Angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis C: a fibrogenic-angiogenic link

Biblos-e Archivo/Manakin Repository

Show simple item record Hernández-Bartolomé, Ángel López-Rodríguez, Rosario Rodríguez-Muñoz, Yolanda Martín-Vílchez, Samuel Borque, María Jesús García-Buey, Luisa C. González-Moreno, Leticia Real, Yolanda Moreno Otero, Ricardo Sanz-Cameno, Paloma P. 2015-05-06T08:37:06Z 2015-05-06T08:37:06Z 2013-06-18
dc.identifier.citation Plos One 8.6 (2013): e66143 en_US
dc.identifier.issn 1932-6203 (online) en_US
dc.description.abstract Aims:Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression, we aimed to determine the value of these angiogenic factors as noninvasive biomarkers of liver fibrosis.Methods:Serum levels of angiopoietin-1 and -2 were measured by ELISA in 108 CHC patients who underwent pretreatment liver biopsy. The correlation between angiopoietins and clinical and demographic variables with liver fibrosis was analyzed by univariate regression. Significant factors were then subjected to multivariate analysis, from which we constructed a novel noninvasive liver fibrosis index (AngioScore), whose performance was validated in an independent series of 71 CHC patients. The accuracy of this model was compared with other documented fibrosis algorithms by De Long test.Results:Angiopoietins correlated significantly with hepatic fibrosis; however, only angiopoietin-2 was retained in the final model, which also included age, platelets, AST, INR, and GGT. The model was validated and behaved considerably better than other fibrosis indices in discriminating all, significant, moderate and severe liver fibrosis (0.886, 0.920, 0.923). Using clinically relevant cutoffs, we classified CHC patients by discarding significant fibrosis and diagnosing moderate and severe fibrosis with greater accuracy, sensitivity, and specificity.Conclusions:Our novel noninvasive liver fibrosis model, based on serum angiopoietin-2 levels, outperforms other indices and should help substantially in managing CHC and monitoring long-term follow-up prognosis en_US
dc.description.sponsorship This work was partially supported by the Ministerio de Ciencia e Innovación (SAF: 2010/21805), CIBERehd (Instituto de Salud Carlos III, Madrid) and Fundación Mutua Madrileña to Ricardo Moreno-Otero and Paloma Sanz-Cameno. Paloma Sanz-Cameno has a grant from Asociación Española Contra el Cáncer (AIO 2010) es_ES
dc.format.extent 9 pag. es_ES
dc.format.mimetype application/pdf en
dc.language.iso eng en
dc.publisher Public Library of Science en_US
dc.relation.ispartof Plos One en_US
dc.rights © 2013 Hernández-Bartolomé et al. es_ES
dc.subject.other antiangiogenic activity en_US
dc.subject.other disease association en_US
dc.subject.other enzyme linked immunosorbent assay en_US
dc.subject.other fibrogenesis en_US
dc.subject.other hepatitis C en_US
dc.title Angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis C: a fibrogenic-angiogenic link en_US
dc.type article en
dc.subject.eciencia Medicina es_ES
dc.identifier.doi 10.1371/journal.pone.0066143 es_ES
dc.identifier.publicationfirstpage e66143 es_ES
dc.identifier.publicationissue 6 es_ES
dc.identifier.publicationlastpage e66143 es_ES
dc.identifier.publicationvolume 8 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion en Reconocimiento es_ES
dc.rights.accessRights openAccess en
dc.authorUAM Moreno Otero, Ricardo (260534)

Files in this item


This item appears in the following Collection(s)

Show simple item record